ExpressGraft (anti-tumor IL-12) / Mallinckrodt - LARVOL DELTA

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers (clinicaltrials.gov) - P1; N=6; Terminated; Sponsor: Stratatech, a Mallinckrodt Company; N=23 ➔ 6; Trial completion date: Nov 2021 ➔ Dec 2020; Active, not recruiting ➔ Terminated; Trial primary completion date: Nov 2021 ➔ Nov 2020; Business decision - not related to product quality or safety concerns

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Diabetes • Metabolic Disorders

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Stratatech, a Mallinckrodt Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers (clinicaltrials.gov) - P1; N=23; Recruiting; Sponsor: Stratatech, a Mallinckrodt Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers (clinicaltrials.gov) - P1; N=23; Not yet recruiting; Sponsor: Stratatech, a Mallinckrodt Company; Trial completion date: Mar 2021 ➔ Sep 2021

Trial completion date

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers (clinicaltrials.gov) - P1; N=23; Not yet recruiting; Sponsor: Stratatech, a Mallinckrodt Company

Clinical • New P1 trial

ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1; N=5; Completed; Sponsor: Stratatech, a Mallinckrodt Company; Active, not recruiting ➔ Completed

Clinical • Trial completion